EP2007415A2 - Combination of an anti-edb fibronectin domain antibody/il2 fusion protein and a further small molecule - Google Patents
Combination of an anti-edb fibronectin domain antibody/il2 fusion protein and a further small moleculeInfo
- Publication number
- EP2007415A2 EP2007415A2 EP07724281A EP07724281A EP2007415A2 EP 2007415 A2 EP2007415 A2 EP 2007415A2 EP 07724281 A EP07724281 A EP 07724281A EP 07724281 A EP07724281 A EP 07724281A EP 2007415 A2 EP2007415 A2 EP 2007415A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- fusion protein
- interleukin
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 60
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 60
- 102000016359 Fibronectins Human genes 0.000 title claims abstract description 48
- 108010067306 Fibronectins Proteins 0.000 title claims abstract description 48
- 150000003384 small molecules Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 164
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 128
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 128
- 238000011282 treatment Methods 0.000 claims abstract description 73
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 69
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 68
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 66
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 55
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 47
- 201000011510 cancer Diseases 0.000 claims abstract description 43
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 38
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 9
- 102000055277 human IL2 Human genes 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 229960005144 gemcitabine hydrochloride Drugs 0.000 claims description 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- 108010067933 oncofetal fibronectin Proteins 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 description 74
- 241000699670 Mus sp. Species 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 71
- 239000000427 antigen Substances 0.000 description 45
- 108091007433 antigens Proteins 0.000 description 43
- 102000036639 antigens Human genes 0.000 description 43
- 239000005557 antagonist Substances 0.000 description 30
- 230000027455 binding Effects 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 27
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 25
- 210000000822 natural killer cell Anatomy 0.000 description 25
- 230000001225 therapeutic effect Effects 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 238000002560 therapeutic procedure Methods 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 22
- 230000000259 anti-tumor effect Effects 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 18
- 210000001165 lymph node Anatomy 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 238000011580 nude mouse model Methods 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 14
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 241000699660 Mus musculus Species 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 230000033115 angiogenesis Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000013595 glycosylation Effects 0.000 description 10
- 238000006206 glycosylation reaction Methods 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 9
- 206010054094 Tumour necrosis Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 210000004923 pancreatic tissue Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 108010087819 Fc receptors Proteins 0.000 description 6
- 102000009109 Fc receptors Human genes 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000012642 immune effector Substances 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 5
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 5
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000001338 necrotic effect Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108010073807 IgG Receptors Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 206010033649 Pancreatitis chronic Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 238000002991 immunohistochemical analysis Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000001173 tumoral effect Effects 0.000 description 4
- 208000012766 Growth delay Diseases 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229940020967 gemzar Drugs 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940127130 immunocytokine Drugs 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101100224495 Drosophila melanogaster Chrac-14 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 102100034681 Myeloblastin Human genes 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 238000011786 NMRI nude mouse Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020004487 Satellite DNA Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 201000005620 dermis tumor Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000487 effect on differentiation Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012837 first-line chemotherapeutic agent Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 102000046661 human PECAM1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 101150111342 nol9 gene Proteins 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Definitions
- the invention relates to a combination of (i) a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognising the extra domain B of fibronectin (ED - B - fibronectin), and (ii) Gemcitabine, and its use for treatment of cancer, in particular pancreatic cancer.
- Adenocarcinoma of the pancreas represents the fifth leading cause of cancer related death in industrialized Western countries.
- the prognosis of patients diagnosed with pancreatic cancer is extremely poor with an estimated overall 5-year survival rate of only 1 -4%.
- Surgical resection provides the only potentially curative treatment, but locally extended or metastasized disease precludes surgical treatment in most cases.
- Rosewicz S Wiedenmann B. Pancreatic carcinoma. Lancet 1997;349:485-489; Cohen SJ, Pinover WH, Watson JC, Meropol NJ. Pancreatic cancer. Curr Treat Options Oncol 2000; 1:375-386).
- chemotherapeutic agents fail to achieve adequate levels within the tumor (Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune F, Mach JP. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993;53:829-836; Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051).
- the clinical de- velopment of systemic TNF ⁇ failed, since the doses that would be necessary for an anticancer efficacy were associated with unacceptable toxicity.
- markers associated with tumor an- giogenesis represents an appealing therapeutic strategy for a number of reasons.
- targets which are selectively expressed around tumor neo-vasculature and in the tumor stroma are easily accessible to intravenously administered antibody derivatives.
- markers of neo-vasculature are typically produced by endothelial cells and/or fibroblasts, which are genetically more stable than tumor cells.
- angiogenesis i.e. the growth of new capillaries from preexisting blood vessels, is characteristic of all aggressive solid tumors, these targets can be regarded as pan-tumoral antigens (Halin C, Zardi L, Neri D. Antibody-based targeting of angiogenesis. News Physiol Sci 2001;16:191- 194; Alessi P, Ebbinghaus C, Neri D. Molecular targeting of angiogenesis. Biochim Biophys Acta 2004; 1654:39-49).
- FN Fibronectin
- ED - B a small domain of 91 amino acids, which is identical in sequence in mouse and man, is usually absent in both plasma and tissue-fibronectin, except for some blood vessels of the regenerating endometrium and the ovaries.
- Viti F Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999;59:347-352).
- Interleukin 2 has been characterized as one of the most potent anti-tumor cytokines. It exhibits a panoply of immune regulatory effects, including the stimulation of various anti-tumor effector cells (Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001;250:462-475). However, despite being approved for the clinical treatment of metastatic renal cell carcinoma, systemically applied IL-2 has not been proven as successful as one had hoped. Therapeutic efficacy of systemically applied IL-2 is thwarted by its serious, potentially life-threatening side effects (e.g.
- IL-2 de- livered systemically further decreases its effectiveness.
- local administration of IL- 2 has been more successful and has resulted in the control of malignant effusions and the generation of significant remission of established lesions (Bubenik J, Den Otter W, Huland E. Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol Immunother 2000;49: 116-122; Den Otter W, Do- browolski Z, Bugajski A, Papla B, Van Der Meijden AP, Koten JW, Boon TA, Siedlar M, Zembala M.
- Intravesical interleukin-2 in Tl papillary bladder carcinoma regression of marker lesion in 8 of 10 patients. J Urol 1998;159:1183-1186; Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 2002;51:492-498; Krastev Z, Koltchakov V, Popov D, Alexiev A, Koten JW, Den Otter W. A case of hepatocellular carcinoma (HCC): treatment with local application of alcohol and interleukin 2 (IL-2). Hepatogastroenterology 2003;50:1647-1649).
- HCC hepatocellular carcinoma
- Tumours cannot grow beyond a certain mass without the formation of new blood vessels (angiogenesis), and a correlation between micro-vessel density and tumour invasiveness has been reported for a number of tumours (Folkmann (1995) Nat. Med., Vol. 1, p. 27).
- Molecules capable of selectively targeting markers of angiogenesis create clinical opportunities for the diagnosis and therapy of tumours and other diseases characterised by vascular proliferation, such as rheumatoid arthritis, diabetic retinopathy and age-related macular degeneration (O'Reilly et al. (1996) Nat. Med. Vol.: 2 p. 689 et seqq; O'Reilly et al. (1997) Cell, Vol.: 88, p.
- EP O 122 707 discloses nucleosides containing difluor-carbohydrate groups for treatment of viruses.
- EP 0 184 365 describes the use of gemcitabine (l-(4-Amino-2-oxo-lH- pyrimidin-l-yl)-2-desoxy-2,2-difluororibose or 2'-deoxy-2',2'-difluorocytidine) as a medicament for the treatment of susceptible neoplasms.
- the synthesis of gemcitabine is described e.g. in EP 0 184 365 and EP 727 433.
- Gamcitabine is to be under- stood as 2'-deoxy-2',2'-difluorocytidine as well as physiologically acceptable salts thereof, in particular the hydrochloride salt thereof.
- the hydrochloride salt of 2'-deoxy- 2',2'-difluorocytidine is commercially available under the trade name Gemzar.
- Pancreatic cancer is a chemoresistant cancer, and standalone radiation therapy of pancreatic cancer does not result in a survival benefit for the patient.
- Several clinical trials describe the combination of radiation therapy plus gemcitabine (Blackstock A.W. et al. J. Clin. Oncol. 17:2208-2212, 1999; Mose S. et al. Strahlenther Onkol. Vol.: 178, pages 59-70, 2002).
- the use of gemcitabine as radiosensitizer in combination with radioimmunotherapy with antibodies for the treatment of pancreatic cancer was investigated in several animal models. Gold DV et al. (Clin. Can.
- Interleukin-2 a four alpha helix bundle cytokine produced by T helper 1 cells, plays an essential role in the activation phases of both specific and natural immune responses (Taniguchi et al. (1993) Cell, Vol.: 73, pages 5 - 8).
- IL-2 promotes proliferation and differentiation of activated T and B lymphocytes and of natural killer (NK) cells, and induces cytotoxic T cell (CTL) activity and NK / lymphokine activated killer (LAK) anti - tumour cytotoxicity.
- CTL cytotoxic T cell
- LAK lymphokine activated killer
- rIL-2 recombinant IL-2
- rIL-2 recombinant IL-2
- adoptively transferred lymphoid cells have resulted in the regression of established tumours in both animal models and patients.
- its in vivo therapeutic efficacy is limited by its rapid clearance and, at high doses, by a severe toxicity mainly related to a vascular leak syndrome (Siegel and Puri (1991) Interleukin-2 tox- icity in J. Clin. Oncol. Vol.: 9 pages 694 - 704).
- Delivery of IL-2 to the tumour site by means of an antibody directed against a cell-surface tumour marker may allow achievement of active local concentrations of IL-2, as well as reducing toxicities associated to systemic administration (Lode et al. (1998) Pharmacol.
- tumour cell surface results in activation and/or targeting of effector cells of the immune system, either CD8 + cytotoxic T cells or natural killer (NK) cells, and in the induction of an efficient anti-tumour immune response.
- T- or NK-cells receive one signal through receptor(s) (for instance T-cell receptor for T cells) specifically recognising appropriate ligands at the tumour cell sur- face, and a second signal through IL-2 receptor chains by IL-2, also localised at the tumour cell surface (Lode et al., 1999, PNAS USA, 96: 8591-8596 and references therein).
- fibronectin a sequence of 91 amino acids identical in mice, rats and humans, which is inserted by alternative splicing into the fibronectin molecule, specifically accumulates around neovascular structures and represents a target for molecular intervention (Zardi et al. (1987) EMBO J. Vol.: 6, pages 2337 - 2342 ; Carnemolla et al. (1989) J. Cell Biol. VoI: 108, pages 1139 - 1148, further Castellani et al, (1994) Int. J. Cancer, Vol. 59, pages 612 - 618).
- Monoclonal antibodies specifically recognising the ED - B - fibronectin domain are described in WO 97/45544.
- Monoclonal antibody Ll 9 is described in WO 99/58570.
- the fusion protein L19IL2 is described for example in the WO 01/62298 .
- WO 01 / 62298 on page 8 line 12 refers to he Ll 9 VH and Ll 9 VL domain sequences described in Pini et al. (1998) J. Biol. Chem. 273: 21769-21776. Pini et al. describes parts of the sequence of L19 in Table II on page 21772.
- L19 has the EMBL accession Num- ber AJ 0061 13.
- the present invention makes available novel and effective medicaments, which are suitable for the treatment of pancreatic cancers.
- the present invention relates to the use of at least one fusion protein for manufacture of a medicament for treatment of pancreatic cancer, wherein the fusion protein comprises an antibody - part, specifically recognising the ED - B-fibronectin domain and an Interleukin-2 part.
- Another embodiment of the present invention relates to a combination comprising at least a fusion protein and gemcitabine, wherein the fusion protein comprises an antibody - part, specifically recognising the ED - B- fibronectin domain and an Interleukin-2 part.
- Gamcitabine is to be understood as 2'-deoxy-2',2'-difluorocytidine as well as physiologically acceptable salts thereof, in particular the hydrochloride salt thereof.
- the hydrochloride salt of 2'-deoxy-2',2'-difluorocytidine is commercially available under the trade name Gemzar.
- NK cells have been considered the predominantly stimulated leukocytes subpopulation by recombinant IL-2 in preclinical and clinical settings (Basse PH, Whiteside TL, Herberman RB. Use of activated natural killer cells for tumor immunotherapy in mouse and human. Methods MoI Biol 2000;121 :81-9;: Janssen RA, Sleijfer DT, Heijn AA, Mulder NH, The TH, de Leij L. Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma. Br J Cancer 1992;66:1177-1179).
- the fusion protein has a N - terminal antibody - part and C - terminal Interleukin-2 part or wherein the fusion protein has a N - terminal Interleukin-2 part and a C - terminal antibody - part.
- the fusion protein comprises a linker connecting the antibody - part and the Interleukin-2 part.
- the antibody-part is human.
- the antibody-part specifically recognising the ED - B domain of fibronectin binds with sub-nanomolar affinity.
- the antibody-part contains at least one of the CDRs of Ll 9 antibody, preferably it contains all CDR sequences of the Ll 9 antibody. In a preferred embodiment, the antibody-part comprises at least one of the SEQ ID. No. 6 to 11. Preferably, the antibody comprises the sequences according to SEQ ID no. 6 to 11.
- the antibody-part comprises at least one V heavy chain according to Seq. Id. No. 01 or at least one V light chain according to Seq. Id. No. 02.
- the antibody part comprises at least one V heavy chain according to Seq. Id. No. 01 and at least one V light chain according to Seq. Id. No. 02.
- the antibody-part comprises one V heavy chain according to Seq. Id. No. 01 and one V light chain according to Seq. Id. No. 02.
- the antibody linker comprises a sequence according to Seq. Id. No. 03, or a sequence having at least 90% identity to the sequence according to Seq. Id. No. 03. In a more preferred embodiment, the antibody linker has a sequence according to Seq. Id. No. 03.
- the Interleukin-2 part is human Interleukin-2 or a functional variant thereof. In a more preferred embodiment, the Interleukin-2 part comprises a sequence according to the Seq. Id No 04.
- the Interleukin-2 part may be glycosylated or unglycosylated.
- the glycosylation pattern may be identical or different from native human Interleukin-2.
- the fusion protein linker comprises a sequence according to the Seq. Id No 05, preferably the fusion protein linker has a sequence according to the Seq. Id No 05.
- the fusion protein linker has a length of 1 to 30 amino acids, more preferred 4 to 25, even more preferred 6 to 20 amino acids.
- the antibody linker has a length of 1 to 20 amino acids, more preferred 4 to 15, even more preferred 6 to 15 amino acids.
- the fusion protein according to the invention is used as a medicament for treatment of pancreatic cancer.
- the fusion protein may be present in monomelic, or multimeric, e.g. homodimeric form in aqeous solution, or mixtures thereof.
- the fusion protein is monomelic, or homodimeric or a mixture thereof.
- the anticancer therapy relates to a combination of a fusion protein according to the invention and gemcitabine.
- the combination is especially useful for cancer therapy.
- Preferred is a combination according to the invention.
- the fusion protein has an N — terminal antibody - part and C - terminal Interleukin-2 part or wherein the fusion protein has an N - terminal Interleukin-2 part and an C — terminal antibody - part.
- the fusion protein comprises a linker connecting the antibody - part and the Interleukin-2 part.
- the antibody-part is human, chimeric or humanized, particularly preferred human.
- the antibody-part specifically recognising the ED - B domain of fibronectin binds with sub-nanomolar affinity.
- the antibody-part contains at least one of the CDRs of Ll 9 antibody, preferably it contains all CDR sequences of the Ll 9 antibody.
- the antibody-part comprises at least one of the SEQ ID. No. 6 to 11.
- the antibody comprises the sequences according to SEQ ID no. 6 to 11.
- the antibody-part comprises at least one V heavy chain according to Seq. Id. No. 01 or at least one V light chain according to Seq. Id. No. 02. in a more preferred embodiment, the antibody part comprises at least one least one V heavy chain according to Seq. Id. No. 01 and at least one V light chain according to Seq. Id. No. 02. In an even more preferred embodiment, the antibody-part comprises one V heavy chain according to Seq. Id. No. 01 and one V light chain according to Seq. Id. No. 02.
- the antibody linker comprises a sequence according to Seq. Id. No. 03, or a sequence having at least 90% identity to the sequence according to Seq. Id. No. 03. In a more preferred embodiment, the antibody linker has a sequence according to Seq. Id. No. 03.
- the Interleukin-2 part is human Interleukin-2 or a functional variant thereof.
- the Interleukin-2 part comprises a sequence according to the Seq. Id No 04.
- the Interleukin-2 part may be glycosylated or unglycosylated. In case of unglycosylated Interleukin-2 the glycosylation pattern may be identical or different from native human Interleukin-2.
- Preferred is the use of the fusion protein according to the invention, wherein the fusion protein linker comprises a sequence according to the Seq. Id No 05, preferably the fusion protein linker has a sequence according to the Seq. Id No 05.
- the fusion protein linker has a length of 1 to 30 amino acids, more preferred 4 to 25, even more preferred 6 to 20 amino acids.
- the antibody linker has a length of 1 to 20 amino acids, more preferred 4 to 15, even more preferred 6 to 15 amino acids.
- the fusion protein according to the invention is used as a medicament for treatment of pancreatic cancer in particular pancreatic carcinoma.
- the invention relates to a combination according to the invention, wherein the cancer is selected from non-small cell lung cancer, head and neck cancer, ovarian and breast cancer, preferably pancreatic cancer.
- a combination is a pharmaceutical composition comprising at least two pharmaceutically active compounds. These compounds can be administered simultaneously or separately with a time gap of 1 minute to several days. The compounds can be administered via the same route or differently; e.g. oral administration of one active compound and parenteral administration of another are possible. Also, the active compounds may be formulated in one medicament, e.g. in one infusion solution or as a kit comprising both compounds formulated separately. Also, it is possible that both compounds are present in two or more packages.
- a composition comprises at least one pharmaceutically active compound together with pharmaceutically acceptable diluents and/or carriers.
- Specifically recognising refers to antibody binding to a predetermined antigen.
- the antibody binds with an affinity of at least about I x 10 ⁇ 7 M "1 , and binds to the predetermined antigen with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.
- the antigen is the ED - B domain of fibronectin.
- Antibody linker is any linker, preferably a peptide linker, which is suitable for linking Vh and Vl domains. Suitable linkers are for example described in Bird et al, Science, 242, 423-426, 1988; Huston et al, PNAS USA, 85, 5879-5883, 1988, EP 0 573 551; EP 0 623679 and EP 0 318554, which documents are introduced by reference.
- Fusion protein linkers are linkers suitable for linking an antibody or antibody-fragment and a second biologically active protein, preferably the linker is peptidic. Suitable linkers are described in EP 0 573 551; EP 0 623679 and EP 0 318554, which documents are introduced by reference. In particular, suitable linkers are described in EP 0 623679.
- Interleukin-2 refers to mammalian Interleukin-2, preferably human Interleukin-2 and functional variants thereof.
- Functional variants of Interleukin-2 are variants of human Interleukin-2 which exhibit at least 10%, but more preferably more than 50%, and even more preferred more than 90% of the activity of native human Interleukin-2.
- Interleukin-2 activities are activities of Interleukin-2 in biochemical assays or in vivo, in particular Interleukin-2 activity can be measured by the effect on proliferation and/or differentiation of activated T and B lymphocytes and of natural killer cells and/or induction of cytotoxic T cell activity and/or NK/lymphokine activated killer (LAK) anti-tumour activity.
- LAK cytotoxic T cell activity and/or NK/lymphokine activated killer
- functional variants are cystein-125 muteins of Inter- leukin-2 as described in EP 0109748 and other muteins, including cystein muteins as described in EPl 36489, in particular serine 125-Interleukin-2.
- the N-terminus of hIL.2 variants may be altered without significantly affecting the activity, in particular the N-terminal 1-5 amino acids, especially preferred the N-terminal Alanine may be deleted or altered, preferably deleted.
- the Interleukin-2 may contain altered or deleted post-translational modifications, in particular the glycosylation pattern may be altered or missing. Different or absent glycosylation may be obtained e.g. either by mutating the sequence or by expression of the fusion protein in an appropriate host.
- Aldesleukin which is approved for metastatic RCC, is unglycosylated des-alanyl-1, serine-125 human interleukine-2 produced in E. coli.
- Antibody-dependent cell-mediated cytotoxicity and “ADCC” refers to a cell- mediated reaction in which non-specific cytotoxic cells that express Fc receptors (FcRs) (e.g. Natural Killer (NK) cells, neutrophils, and macrophages) recognise bound antibody on a target cell and subsequently cause lysis of the target cell.
- FcRs Fc receptors
- FcR expression on haematopoietic cells in summarised is Table 3 on Page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991).
- ADCC activity of a molecule of interest may be assessed in vitro, such as that described in US Patent No. 5,500,362 or 5,821, 337.
- useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
- PBMC peripheral blood mononuclear cells
- NK Natural Killer
- ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).
- Human effector cells are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least Fc ⁇ RIII and carry out ADCC ef- fector function.
- human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells being preferred.
- PBMC peripheral blood mononuclear cells
- NK natural killer cells
- Fc receptor or “FcR” are used to describe a receptor that binds to the Fc region of an antibody.
- the preferred FcR is a native sequence human FcR.
- a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes re- ceptors of the Fc ⁇ RI, Fc ⁇ RII, and Fc ⁇ RIII subclasses, including allelic variants and alternatively spliced forms of these receptors.
- Fc ⁇ RII receptors include Fc ⁇ RIIA (an “activating receptor") and Fc ⁇ RIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof.
- Activating receptor Fc ⁇ RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cy- toplasmic domain.
- ITAM immunoreceptor tyrosine-based activation motif
- Inhibiting receptor Fc ⁇ RIIB contains an immunoreceptor tyrosine- based inhibition motif (ITIM) in its cytoplasmic domain.
- ITIM immunoreceptor tyrosine- based inhibition motif
- the term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the foetus (Guyer et al., J. Immunol. 1 1 7587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).
- FcRn neonatal receptor
- Antibody - part comprises an antibody as defined below.
- the term "antibody” herein is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.
- the antibody is human, chimeric or humanized, particularly preferred human.
- Antibody fragments comprise a portion of an intact antibody, preferably comprising the antigen-binding or variable region thereof.
- antibody fragments include: Fab, Fab', F(ab') 2 and Fv fragments, single chain Fv fragments; diabodies; minibodies, nanobodies, linear antibodies; single-chain antibody molecules; and multispecific anti- bodies formed from antibody fragments.
- the antibody fragment is human, chimeric or humanized, particularly preferred human.
- “Native antibodies” are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains.
- Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes.
- Each heavy and light chain also has regularly spaced intrachain disulfide bridges.
- Each heavy chain has at one end a variable domain (V H ) followed by a number of constant domains.
- Each light chain has a variable domain at one end (V L ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain.
- Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains.
- variable refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework regions (FRs).
- the variable domains of native heavy and light chains each comprise four FRs, largely adopting a ⁇ -sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the ⁇ - sheet structure.
- the hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (See Kabat et al, Sequences of Proteins Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)).
- the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC).
- Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab” fragments, each with a Single antigen-binding site, and a residual "Fc” fragment, whose name reflects its ability to crystallize readily.
- Pepsin treatment yields F(ab') 2 fragment that has two antigen-binding sites and is still capable of cross-linking antigen.
- Fv is the minimum antibody fragment which contains a complete antigen-recognition and antigen-binding site. This region consists of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the V H -V L dimer.
- the six hypervariable regions confer antigen-binding specificity to the antibody.
- a single variable domain or half of an Fv comprising only three hypervariable regions specific for an antigen
- the Fab fragment also contains the constant domain of the light chain and the first constant domain (CHl) of the heavy chain.
- Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHl domain including one or more cysteines from the antibody hinge region.
- Fab' -SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear at least one free thiol group.
- F(ab') antibody fragments originally were produced as pairs of
- the "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (K) and lambda (X), based on the amino acid sequences of their constant domains.
- antibodies can be assigned to different classes. There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgA, and IgA2.
- the heavy-chain constant domains that correspond to the different classes of antibodies are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ respectively.
- the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
- Single-chain Fv or ' scFv " antibody fragments comprise the V H and V L domains of antibody, wherein these domains are present in a single polypeptide chain.
- the Fv polypeptide further comprises a polypeptide linker between the VH and V L , do- mains which enables the scFv to form the desired structure for antigen binding.
- antibodies or antibody fragments can be isolated from anti- body phage libraries generated using the techniques described in McCafferty et al, Nature, 348552-554 (1990). Clackson et ai, Nature, 352:624-628 (1991) and Marks et al, J. MoI. Biol, 222581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries.
- non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen- combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.
- diabodies refers to small antibody fragments with two antigen-binding sites. Such fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) in the same polypeptide chain (V H - V L ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen- binding sites. Diabodies are described more fully in, for example, EP 0 404 097; WO 93/11161 ; and Hollinger et al, Proc. Natl. Acad ScL USA, 905444-6448 (1993).
- the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, Le., the individual antibodies com- prising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncon- taminated by other immunoglobulins.
- the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al, Nature, 256: 495 (1975), or may be made by recombinant DNA methods (See, e.g., U.S. Patent No. 4,816,567).
- the “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al, Nature, 352:624-628 (1991) and Marks et al, J. MoI. Biol, 222581-597 (1991), for example.
- the monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or ho- mologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,s 16,567; Morrison et al, Proc. Natl Acad. Sci. USA, 8 1 :685 1-6855 (1984)).
- chimeric antibodies immunoglobulins in which a portion of the heavy and/or light chain is identical with or ho- mologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding
- Chimeric antibodies of interest herein include "primatised” antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey, such as baboon, rhesus or cynomolgus monkey) and human constant region sequences (US Pat No. 5,693,780).
- Humanised antibodies Methods for humanising non-human antibodies have been described in the art.
- a humanised antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid resi- dues are often referred to as "import" residues, which are typicality taken from an "import” variable domain.
- Humanisation can be essentially performed following the method of Winter and Co-workers (Jones et al, Nature, 321522-525 (1986); Riechmann et al, Nature, 332:323-327 (1988); Verhoeyen et al, Science, 239: 1534-1536 (1988)), by sub- stituting hypervariable region sequences for the corresponding sequences of a human antibody.
- "humanised" antibodies are chimeric antibodies (U.S. Patent No. 4,8 16,567) wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
- humanised antibodies are typically human antibodies in which some hypervariable re- gion residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
- the choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity.
- the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework region (FR) for the humanised antibody (Sims et al., J. Immunol., 151 :2296 (1993); Chothia et al., J. MoI.
- Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanised antibodies (Carter et al, Proc. Natl Acad. Sci. USA,
- humanised antibodies are prepared by a process of analysis of the parental sequences and vari- ous conceptual humanised products using three - dimensional models of the parental and humanized sequences. Three - dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences.
- Human antibodies As an alternative to humanisation, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunisation, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production.
- JH antibody heavy-chain joining region
- phage display technology can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors.
- V domain genes are cloned in- frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M 13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties.
- the phage mimics some of the properties of the B cell.
- Phage display can be performed in a variety of formats; for their review see, Johnson, Kevin S. and Chiswell, David J., Current Opinion in Structural Biology 3:564-571(1993).
- V-gene segments can be used for phage display. Clackson et al., Nature, 352:624-628 (1991) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice.
- a repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self- antigens) can be isolated essentially following the techniques described by Marks et al., J MoI. Biol. 222581-597 (1991), or Griffith et. al, EMBO J 12:725-734 (1993). See, also, US Patent Nos. 5,565,332 and 5,573,905. Human antibodies may also be generated by in vitro activated B cells (see US Patents 5,567,610 and 5,229,275).
- hypervariable region when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding.
- the hypervariable region comprises amino acid residues from a "complementarily determining region” or "CDR" (e.g. residues 24-34 (Ll), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (Hl), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (e.g.
- Antibody fragments Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (See, e.g., Morimoto et al, Journal of Biochemical und Biophysical Methods 24: 107-1 17 (1992) and Brennan et al, Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. For example, the antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab') 2 fragments (Carter et al., Biotechnology 10: 163- 167 (1992)).
- F(ab') 2 fragments can be isolated directly from recombinant host cell culture.
- the antibody of choice is a single chain Fv fragment (scFv). See WO 93/16185; US Patent NO. 5,571,894; and US Patent No. 5,587,458.
- the antibody fragment may also be a "linear antibody", e.g., as described in US Patent 5,641,870 for example. Such linear antibody fragments may be monospecific or bispecif ⁇ c.
- the term "specifically recognising" refers to antibody binding to a predetermined antigen.
- the antibody binds with an affinity of at least 1 x 10 "7 M, and binds to the ED - B domain of fibronectin that is at least two-fold greater than the affinity for binding to a non-specific antigen (e.g. BSA, casein) other than ED - B domain of fibronectin.
- a non-specific antigen e.g. BSA, casein
- Amino acid sequence modification(s) of protein or Peptide antagonists or antibody - part described herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antagonist.
- Amino acid sequence variants of the antagonist are prepared by introducing appropriate nucleotide changes into the antagonist nucleic acid, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and or substitutions of, residues within the amino acid sequences of the antagonist. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics.
- a variation of 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18, 19 or 20 amino acids can be executed.
- Interleukin-2 a variation of 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18, 19, 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; or 33 amino acids can be executed.
- a linker a variation of 1; 2; 3; 4; 5; 6; or 7 amino acids can be executed.
- a variation is defined as a deletion, insertion and/or substitution.
- the amino acid changes also may alter post-translational processes of the antagonist, such as changing the number or position of glycosylation sites.
- a useful method for identification of certain residues or regions of the antagonist that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and WeIk Science, 244: 108 1-1085 (1989).
- a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and GIu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with antigen.
- Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution.
- the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, Ala scanning or random mutagenesis is conducted at the target codon or region and the expressed antagonist variants are screened for the desired activity.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
- terminal insertions include an antagonist with an N-terminal methionyl residue or the antagonist fused to a cytotoxic polypeptide.
- Other insertional variants of the antagonist molecule include the fusion to the N- or C-terminus of the antagonist of an enzyme, or a polypeptide which increases the serum half-life of the antagonist.
- Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the antagonist molecule replaced by a different residue.
- the sites of greatest interest for substitutional mutagenesis of antibody antagonists include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions".
- Substantial modifications in the biological properties of the antagonist are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
- Naturally occurring residues are divided into groups based on common side-chain properties:
- hydrophobic Norleucine, Met, Ala, VaI, Leu, He
- neutral hydrophilic Cys, Ser, Thr
- Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
- Any cysteine residue not involved in maintaining the proper conformation of the antagonist also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant cross linking.
- cysteine bond(s) may be added to the antagonist to improve its stability (particularly where the antagonist is an antibody fragment such as a Fv fragment).
- a particularly preferred type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody.
- the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated.
- a convenient way for generating such substitutional variants is affinity maturation using phage display.
- hyper- variable region sites e.g. 6-7 sites
- the antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M 13 packaged within each particle.
- the phage-displayed variants are then screened for their biological activity (e.g. binding affinity) as herein disclosed.
- alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding.
- Such contact residues and neighbouring residues are candidates for substitution ac- cording to the techniques elaborated herein.
- the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.
- Another type of amino acid variant of the antagonist alters the original glycosylation pattern of the antagonist. By altering it is meant to delete one or more carbohydrate moie- ties found in the antagonist, and/or adding one or more glycosylation sites that are not present in the antagonist.
- Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue.
- the tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain.
- O- linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
- Addition of glycosylation sites to the antagonist is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tri- peptide sequences (for N-linked glycosylation sites).
- the alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antagonist (for O-linked glycosylation sites).
- Nucleic acid molecules encoding amino acid sequence variants of the antagonist are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non- variant version of the antagonist.
- ADCC antigen-dependent cell-mediated cyotoxicity
- CDC complement dependent cytotoxicity
- This may be achieved by introducing one or more amino acid substitutions in an Fc region of an anti- body antagonist.
- cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region.
- the homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al, J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J.
- Homodimeric antibodies with enhanced anti-tumour activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 53:2560-2565 (1993).
- an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al. Anti-Cancer Drug Design 3:219-230 (1989).
- L19IL2 is used according to the invention, which comprises the sequences according to SEQ ID. No 4.
- L19IL2 is used according to the invention, which comprises the sequences according to SEQ ID. No 6 to 11.
- L19IL2 is used according to the invention, which comprises the sequences according to SEQ ID. No. 1, 2, 3, 4, and 5.
- the L19IL2 fusion protein contains variations compared to the sequences according to SEQ ID. No. 1, 2, 3, 4, and 5. Variations of the fusion protein L19IL2 are defined by variations as mentioned before.
- amino acids in the L19IL2 molecule may be modified according to Table 2, by deletion, insertion and / or substitution of amino acids compared to those defined by SEQ ID. No. 1, 2, 3, 4, and 5:
- the combination of the invention exhibits pharmacological activity.
- the combination shows pharmacological activity in a number of pathological or disease states in connection with a cancer, especially pancreatic cancer.
- the combination of the invention is therefore indicated for use in treatment of non-small cell lung cancer, head and neck cancer, colon, ovarian and breast cancer, especially pancreatic cancer.
- the fusion protein and gemcitabine may be administered simultaneously or separately, at different times.
- an indicated repeat dose of the fusion protein L19IL2 in man is in the range of about 1-100 Mio IL-2 equivalent IU as a fixed dose, preferred 5-30 Mio IL-2 equivalent IU as a fixed dose per application.
- the antibody must be given in a dose that does not cause toxicity of the most sensitive organ in the body (dose limiting organ).
- dose limiting organ For anti- bodies, the kidney might be the dose limiting organ and impact on the cardiovascular system might be dose-limiting for L19IL2.
- Specific binding members of the present invention may be administered to a patient in need of treatment via any suitable route, usually by infusion into the bloodstream and/or directly into the site to be treated, e.g. tumor.
- the precise dose will depend upon a number of factors, the route of treatment, the size and location of the area to be treated (e.g. tumour), the precise nature of the antibody (e.g. whole antibody, scFv molecule), and the nature of any detectable label or other molecule attached to the antibody.
- Treatments may be repeated at daily, twice- weekly, weekly or monthly intervals, at the discretion of the physician.
- the dose of gemcitabine administered will vary according to the mode of use and route of use, as well as to the requirements of the patient. In general, a weekly application is preferred over a daily dosing for a systemic therapy of adult patients. For the most commonly appliced once-weekly schedule the standard dose for gemcit- abine is 1000-1250 mg/m 2 as an intravenous infusion over 15 to 30 minutes.
- a method of treatment of cancer especially non-small cell lung cancer, head and neck cancer, colon, ovarian and breast cancer, especially pancreatic cancer, which method comprises an administration of a pharmaceutical composition of L19IL2 in combination with gemcitabine, wherein the amount of combination suppresses the disease and wherein the pharmaceutical composition of the combination is given to a patient, who is in need thereof;
- a pharmaceutical composition comprising L19IL2 and gemcitabine.
- the preferred method of administration is parenteral, in particular intravenous infusion.
- IL-2 is one of the most potent known anti-tumor cytokines. However, the efficacy of systemically applied IL-2 has been offset by accompanying toxicities.
- human pancreatic carcinomca cell lines MiaPaca American Type Culture Collection
- DanG and murine lymphoma cell line YAC-I Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH, Braun- schweig, Germany
- DEM Dulbecco's Eagle medium
- HBSS Hanks' Balanced Salt Solution
- Antibiotic/ Antimycotic Solution glutamine and hygromycin B
- FCS fetal calf serum
- trypsin/EDTA penicillin, and streptomycin
- Biochrom, Berlin, Germany human fusion protein L19IL2 and human homodimeric scFv antibody fragment Ll 9
- Ficoll-Paque Plus Amersham, Braunschweig, Germany
- collagenase Type 3 Worthington, NJ, USA
- AmpliTaq Gold DNA polymerase Applied Biol
- pancreatic carcinoma 17 chronic pancreatitis and 13 normal pancreatic tissue samples were obtained from individuals who underwent surgical resection at the Department of Surgery at Charite University Hospital. This study was approved by the local ethics committee and all patients gave written informed consent prior to surgery.
- the human pancreatic carcinoma cell lines DAN-G and MiaPaca and the murine lym- phoma cell line YAC-I were cultured as previously described. (Wagner K, Scholz A,
- MiaPaca cells stably transfected with an Angiopoetin 2 DNA construct, were maintained as MiaPaca wild type cells, except for the addition of hygromycine B at a concentration of 300 ⁇ g/ml.
- mice Female NMRI nude mice (age, approx. 10 weeks; weight 21-25g) were purchased from Bomholtgard (Ry, Denmark). Animal care followed institutional guidelines and all experiments were approved by local animal research authorities.
- Three orthotopic xenograft mouse models of pancreatic carcinoma were established, including two non-metastatic models by injection of wild type cells of the human pancreatic carcinoma cell lines DanG and MiaPaca, and one metastatic model by implantation of MiaPaca cells stably transfected with an Angiopoetin 2 DNA construct (MiaPaca- A2) (established by A. Scholz, unpublished data). Orthotopic transplantation was carried out as described.
- mice were anesthetized by intrap- eritoneally (i.p.) administering a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). After median laparotomy, the peritoneum was opened, and the pancreas was exposed.
- mice were randomised and groups of 10-12 mice were intravenously (i.v.) treated with vehicle (0,9% saline), untargeted IL-2, homodimeric scFv Ll 9 or L19-IL-2, consisting of IL-2 conjugated to the homodimeric scFv Ll 9 or i.p. administered together with gemcitabine according to different protocols as described in the results section. All therapeutic agents were diluted in 0.9% saline and applied in a volume of 1/ ⁇ l/g BW. After termination of therapy, mice were killed, blood samples were collected and tumor volume was calculated using the formula length x width x depth x ⁇ /6.
- mice were kept alive after completion of therapy to obtain long term data.
- mouse blood samples were taken by ret- roorbital bleeding with heparinized blood collection capillaries to assay serum CA 19-9 levels. Survival time of mice was followed until day 100 after cessation of therapy (day 121 after tumor cell transplantation). Mice were considered to be cured if there was no detectable tumor at day 100.
- mice were injected i.p. with 50/ ⁇ l anti asialo-GM-1 (ASGMl) Ab 3 days before tumor cell injection and every 4 days for a total of 6 injections. Quality of NK cell depletion was monitored by flow cytometry and cytotoxicity assay.
- ASGMl anti asialo-GM-1
- Mononuclear cells were prepared from the spleens of mice depleted for NK cells or not as described elsewhere. Briefly, spleens were removed under deep general anesthesia and digested with collagenase for I/hour at 37°C. Subsequently, contents were forced through a 100 ⁇ m cell strainer and washed twice with HBSS. Mononuclear cells were separated from the cell suspension by running a Ficoll-Hypaque density gradient cen- trifugation.
- Surgically resected human and murine tissue samples were snap-frozen in liquid nitrogen and after fixation in PFA 4%, pH 7 for 20 minutes, 4 ⁇ m cryostat sections of the frozen tissue were analyzed immunohistochemically using the avidin-biotin-technique as described previously.
- Apoptotic cells were proven by Terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay using TumorTACS in situ Apoptosis Detection Kit. Both procedures were carried out following the manufacturer's instructions except that 3-amino-9-ethylcarbazole (AEC) was used as the substrate-chromogen. Negative controls were included by omitting the pri- mary antibody (Animal Research Kit) or the terminal deoxynucleotidyl transferase (TUNEL).
- TUNEL Terminal deoxynucleotidyl transferase mediated dUTP nick end labeling
- Quantitative immunohistochemical analysis for the area of vital (non- necrotic) tumor tissue was carried out by computer aided imaging analysis using Axiovi- sion 4.2 software (Zeiss, Jena, Germany).
- Axiovi- sion 4.2 software Zeiss, Jena, Germany.
- 20 randomly selected measurement areas (680 x 510 ⁇ m, mag- nification x 20) of each tumor specimen were analyzed and for evaluation of ED - B FN expression, 10 areas (1390/x/1000 ⁇ m, magnification x 10) were scanned.
- results represent the positive staining as a percentage of measurement area (inflammatory cells, ED - B FN) or the ratio of positive tumor cells as a percentage of total tumor cells (Ki67, TUNEL), respectively.
- H&E sections were scanned at low power (x 2,5). Total and necrotic tumor area was marked on the screen and areas were calculated by the image analysis system, and the ratio tumor necrosis area/total tumor area was given in percentages.
- Genomic DNA of mouse lymph nodes was extracted using the QIAamp DNA Mini Kit according to the manufacturer's recommended protocol.
- the presence of human specific DNA was proven by polymerase chain reaction (PCR) amplifying an 850 bp fragment of the ⁇ -satellite region of the human chromosome 17 using the forward primer 5 ⁇ - gggataatttcagctgactaacacg-3 ⁇ and the reverse primer 5 ⁇ -ttccgtttagttaggtgcagttatc-3 ⁇ according to the protocol reported by Becker et al.
- PCR polymerase chain reaction
- Serum parameters Mouse blood samples were obtained by retroorbital bleeding or decapitation. Samples were centrifuged and supernatants were stored at -20°C. Serum CA 19-9 levels were measured by a fully automated chemiluminescence immunoassay on an ADVIA Centaur (Bayer, Leverkusen, Germany) and eipase levels were determined using a kinetic col- orimetric assay on an ADVIA 2400 (Bayer, Leverkusen, Germany).
- mice were orthotopically injected with the human pancreatic cancer cell line DanG. After establishment of solid tumors, mice were randomized to receive 0.9% saline or 1.43 MIU/kg BW or 4.29 MIU/kg BW IL-2 equivalents of either L19IL2 or untargeted IL-2 for 10 days. At the end of therapy, all mice were sacrificed and the tumor volume was calculated.
- mice treated with saline or either targeted or untargeted IL-2 were assayed for serum lipase levels as a surrogate marker of pancreatitis.
- L19IL2 significantly reduces or eliminates established metastases of pancreatic cancer Having proven efficacy of L19IL2 for treatment of primary pancreatic tumors, we next explored its potency in metastatic disease. Therefore, mice were orthotopically engrafted with MiaPaca cells, stably transfected with an Ang2 DNA construct (MiaPaca-A2), re- suiting in a metastatic spread of pancreatic cancer to intraabdominal lymph nodes and liver. Metastases were verified by immunohistochemical staining for human pancy- tokeratin and subsequently investigated for ED - B FN expression.
- mice bearing orthotopic MiaPaca-A2 pancreatic tumors with pre-established lymph node metastases were randomly treated with vehicle or Ll 9IL2 at 4.29 MIU/kg BW for 10 days (days 60-64 and 67-71). At the end of therapy, all mice were sacrificed and the primary tumor volume as well as the lymph node area was calcu- lated.
- Verification of lymph node metastases by immunostaining for pancytokeratin revealed large, polymorphnuclear cells with strong immunoreactivity for cytokeratin in lymph nodes of 80% of control mice compared to 20% of L19IL2 treated mice.
- mice orthotopi- cally injected with DanG cells were randomly assigned to control group or treatment with 4.29 MIU/kg BW L19IL2 according to the following protocols (a) once weekly, on days 7, 14; (b) thrice weekly, on days 7,9,11,14,16,18; (c) five times by the week, on days 7-11 and 14-18 (Fig 4, left panel). Compared to controls, all regimens resulted in a significant tumor growth delay.
- mice bearing orthotopic DanG pancreatic cancer were treated with 4.29 MIU/kg BW L19IL2 for 10 days (days 7-11 and 14-18). Subsequently, mice were left untreated and tumor relapse was monitored by biweekly evaluation of serum CA 19-9 levels. Between the fourth and the eighth week after termination of therapy, six out of 10 mice experienced a marked elevation of serum tumor marker associated with tumor relapse and subsequently died due to tumor burden. One animal developed a dermal tumor without any increase of serum CA 19-9 level. Four out of 10 mice survived without boost of serum CA 19-9 levels throughout the observation period of three months after cessation of therapy. Autopsy preformed at this time point consistently revealed no evidence of tu- mor recurrence, and animals were considered to be cured (Fig 5).
- Gemcitabine is considered the best currently available cytotoxic drug for treating pan- creatic cancer.
- L19IL2 treatment to gemcitabine and assessed whether a combinatorial treatment of these two agents may yield any therapeutical benefit.
- standard pancreatic cancer treatment of mice bearing orthotopic DanG tumors with gemcitabine i.p. injection of 250 mg/kg BW once weekly, i.e. on day 7 and 14
- L19IL2 treatment i.v. injection of 4.29 MIU/kg BW on days 8-12 and 15-19
- mice orthotopically engrafted with DanG cells were randomly assigned to the following treatment groups: NK competent + saline treatment, NK deficient + saline treatment, NK deficient + L19IL2 treatment (4.29 MIU/kg BW Ll 9 on days 7-11, 14-18) and NK competent + L19IL2 treatment (4.29 MIU/kg BW L19 on days 7-11, 14-18).
- L19IL2 treatment did not yield any significant tumor regression in NK deficient mice as compared to NK deficient or NK competent vehicle treated mice.
- L19IL2 was more than 5 fold more effective in NK competent in comparison with NK deficient mice (Fig 8C).
- FIG. 1 Expression of ED - B FN in human pancreatic carcinoma and in two orthotopic nude mouse models of pancreatic cancer.
- ED - B FN expression was quantified by com- puter aided image analysis. Values given represent the immunostained area as a percentage of measurement frame area with the lines indicating the mean ED — B FN amount of each group. *: p ⁇ 0.001 versus human pancreatic carcinoma .
- FIG. 1 Therapeutic effects of L19IL2 against orthotopic pancreatic cancer in nude mice.
- A-C Nude mice were orthotopically injected with the human pancreatic cancer cell line DanG. After establishment of solid tumors, groups of 10-12 mice were randomly treated as indicated for 10 days (days 7-11, 14-18 after tumor cell transplantation). All mice were sacrificed on day 21 and tumor volume was calculated (A, C).
- A) Left panel: Mice were administered with either 0.9% saline or with the indicated concentrations of IL-2 equivalents as either L19IL2 or untargeted IL-2. Data shown represent the mean tumor volume ⁇ SEM of each treatment group. *: p ⁇ 0.004 (versus control); +: p 0.0003 (versus equimolar amounts of IL-2).
- mice were treated with saline, 4.29 MIU/kg BW L19IL2 or equimolar amounts of the homodimeric scFvL19 antibody fragment. Values are expressed as the percentage of tumor volume from vehicle treated controls. *: p ⁇ 0.004 (versus control and Ll 9).
- mice treated with vehicle or L19IL2 were collected at the indicated time points and serum CA 19-9 levels were determined. Each point represents the mean ⁇ SEM of control or treatment group. *: p ⁇ 0.05.
- C Mice were randomly assigned to the indicated treatment groups. At the end of treatment, blood samples were collected and serum lipase was analyzed by a kinetic colorimetric assay. Values shown are the mean ⁇ SEM of each treatment group.
- D Nude mice were orthotopically transplanted with the human pancreatic cancer cell line MiaPaca.
- FIG. 3 Therapeutic effects of L19IL2 on established metastases of orthotopic pancreatic cancer xenografts in nude mice.
- Nude mice were orthotopically injected with cells of the human pancreatic cancer cell line MiaPaca, stably transfected with an Angiopo- etin-2 DNA construct, resulting in metastatic spread of pancreatic cancer to intraabdominal lymph nodes and liver.
- the area of lymph nodes was calculated by determining the largest diameter and its perpendicular diameter and computing the product of the two measurements. Values given represent the median lymph node area ⁇ SEM of control and treatment group. Lymph nodes were analyzed for tumor infiltration by immunostain- ing for pancytokeratin.
- FIG. 4 Schedule dependent anti-tumor effects of L19-IL-2. Nude mice bearing orthotopic DanG pancreatic tumors were i.v. administered with vehicle (0.9% saline) or 4.29 MIU/kg BW L19IL2 according to the treatment schedules depicted on the left panel. All mice were killed at day 21 and pancreatic tumor volume was calculated (right panel). Data shown represent the mean ⁇ SEM of each treatment group. *: p ⁇ 0.0001 versus saline control.
- FIG. 5 Long term effects of L19IL2 treatment. 10 nude mice bearing orthotopic DanG pancreatic cancer were treated with 4.29 MIU/kg BW L19IL2 on days 7-11, 14-18 after tumor cell transplantation and were subsequently left untreated. At the end of therapy and repeated biweekly, mouse blood samples were collected and serum CA 19-9 levels were determined. Data shown represent the serum CA 19-9 levels of each individual animal.
- FIG. 7 Effects of L19IL2 on tumor necrosis, apoptosis and proliferation.
- Mice bearing orthotopic DanG tumors were i.v. treated with either 0.9% saline or 4.29 MIU/kg BW L19IL2.
- Left panel After termination of therapy, tumors were examined by conventional H&E staining (A), apoptosis was assessed by TUNEL assay (B) and proliferating cells were visualized by Ki67 staining (C). Representative examples of vehicle-treated and L19IL2 treated tumors are shown.
- FIG. 8 Identification of the immune effector cells mediating L19IL2 induced tumor regression.
- A, B Nude mice, bearing orthotopic DanG pancreatic tumors were i.v. administered with 0.9% saline or 4.29 MIU/kg BW L19-IL-2. After completion of therapy, tumors were stained with a CDl Ib antibody recognizing predominantly macrophages (A) and with an NKl.1 antibody specific for NK cells (B).
- Left panel Representative examples of vehicle-treated (and L19IL2 treated mice are shown. (Bar, lOO ⁇ m). Infiltration of CDl lb+ cells (A) and of NK cells (B) was quantified via computer aided image analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07724281A EP2007415B1 (en) | 2006-04-07 | 2007-04-05 | Combination of an anti-edb fibronectin domain antibody/il2 fusion protein and a further small molecule |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06090054A EP1842553A1 (en) | 2006-04-07 | 2006-04-07 | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
US79686606P | 2006-05-03 | 2006-05-03 | |
PCT/EP2007/003343 WO2007115837A2 (en) | 2006-04-07 | 2007-04-05 | Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule |
EP07724281A EP2007415B1 (en) | 2006-04-07 | 2007-04-05 | Combination of an anti-edb fibronectin domain antibody/il2 fusion protein and a further small molecule |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2007415A2 true EP2007415A2 (en) | 2008-12-31 |
EP2007415B1 EP2007415B1 (en) | 2010-09-22 |
Family
ID=36811417
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06090054A Withdrawn EP1842553A1 (en) | 2006-04-07 | 2006-04-07 | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
EP07724281A Not-in-force EP2007415B1 (en) | 2006-04-07 | 2007-04-05 | Combination of an anti-edb fibronectin domain antibody/il2 fusion protein and a further small molecule |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06090054A Withdrawn EP1842553A1 (en) | 2006-04-07 | 2006-04-07 | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
Country Status (8)
Country | Link |
---|---|
US (1) | US7851599B2 (en) |
EP (2) | EP1842553A1 (en) |
JP (1) | JP5096456B2 (en) |
AT (1) | ATE481979T1 (en) |
CA (1) | CA2648109C (en) |
DE (1) | DE602007009373D1 (en) |
ES (1) | ES2352161T3 (en) |
WO (1) | WO2007115837A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19932688B4 (en) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design of beta-sheet proteins of gamma-II-crystalline antibody-like |
DE10324447A1 (en) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generation of artificial binding proteins based on ubiquitin |
US20090110680A1 (en) * | 2006-04-07 | 2009-04-30 | Stephanie Sieger | Combination of an anti ED-B fibronectin domain antibody and gemcitabine |
EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
ES2382058T3 (en) | 2008-01-17 | 2012-06-04 | Philogen S.P.A. | Combination of a fusion protein of an antibody directed against the fibronectin-IL-2 EDB, and a B-lymphocyte-binding molecule, progenitors of B-lymphocytes and / or their cancerous counterparts |
EP2367843B1 (en) | 2009-12-14 | 2014-10-08 | Scil Proteins GmbH | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
EP2721152B1 (en) | 2011-06-15 | 2019-03-27 | Navigo Proteins GmbH | Dimeric binding proteins based on modified ubiquitins |
WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
US20150216937A1 (en) * | 2012-03-29 | 2015-08-06 | Altor Bioscience Corporation | Methods for treating neoplasia |
WO2014194784A1 (en) * | 2013-06-06 | 2014-12-11 | 合肥立方制药股份有限公司 | Human antibody against ed-b domain of fibronectin and uses thereof |
CA2975362A1 (en) | 2015-02-06 | 2016-08-11 | Navigo Proteins Gmbh | Egfr binding proteins comprising ubiquitin muteins |
KR102064396B1 (en) | 2015-07-16 | 2020-01-09 | 나피고 프로타인스 게엠베하 | Novel immunoglobulin-binding proteins and their use in affinity purification |
WO2017013136A1 (en) | 2015-07-20 | 2017-01-26 | Scil Proteins Gmbh | Novel binding proteins based on di-ubiquitin muteins and methods for generation |
CN109310780A (en) | 2016-05-04 | 2019-02-05 | 纳维格蛋白质有限公司 | The target compound being coupled for chemical part site-specificity comprising peptide linker |
CN117736281A (en) | 2016-08-11 | 2024-03-22 | 瑞普利金公司 | Alkaline stable FC binding proteins for affinity chromatography |
IL310865A (en) * | 2016-10-17 | 2024-04-01 | Pfizer | Anti-edb antibodies and antibody-drug conjugates |
GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
EP3688023A4 (en) * | 2017-09-25 | 2021-06-30 | Dingfu Biotarget Co., Ltd | Methods and compositions for cancer treatment |
US11414466B2 (en) | 2017-11-07 | 2022-08-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer |
EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
WO2023180409A1 (en) | 2022-03-23 | 2023-09-28 | Philogen S.P.A | Il2 immunoconjuqate preparation |
WO2024047237A1 (en) | 2022-09-01 | 2024-03-07 | Philogen S.P.A. | Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
ATE526039T1 (en) * | 2000-02-24 | 2011-10-15 | Philogen Spa | COMPOSITIONS AND METHODS FOR TREATING ANGIOGENESIS IN PATHOLOGICAL DEFECTS |
-
2006
- 2006-04-07 EP EP06090054A patent/EP1842553A1/en not_active Withdrawn
-
2007
- 2007-04-04 US US11/783,274 patent/US7851599B2/en not_active Expired - Fee Related
- 2007-04-05 JP JP2009503502A patent/JP5096456B2/en not_active Expired - Fee Related
- 2007-04-05 WO PCT/EP2007/003343 patent/WO2007115837A2/en active Application Filing
- 2007-04-05 AT AT07724281T patent/ATE481979T1/en active
- 2007-04-05 ES ES07724281T patent/ES2352161T3/en active Active
- 2007-04-05 DE DE602007009373T patent/DE602007009373D1/en active Active
- 2007-04-05 CA CA2648109A patent/CA2648109C/en not_active Expired - Fee Related
- 2007-04-05 EP EP07724281A patent/EP2007415B1/en not_active Not-in-force
Non-Patent Citations (1)
Title |
---|
See references of WO2007115837A3 * |
Also Published As
Publication number | Publication date |
---|---|
JP2009532408A (en) | 2009-09-10 |
EP2007415B1 (en) | 2010-09-22 |
JP5096456B2 (en) | 2012-12-12 |
EP1842553A1 (en) | 2007-10-10 |
ES2352161T3 (en) | 2011-02-16 |
US7851599B2 (en) | 2010-12-14 |
WO2007115837A3 (en) | 2008-01-24 |
DE602007009373D1 (en) | 2010-11-04 |
WO2007115837B1 (en) | 2008-03-27 |
WO2007115837A2 (en) | 2007-10-18 |
CA2648109A1 (en) | 2007-10-18 |
ATE481979T1 (en) | 2010-10-15 |
US20090110660A1 (en) | 2009-04-30 |
CA2648109C (en) | 2012-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2007415B1 (en) | Combination of an anti-edb fibronectin domain antibody/il2 fusion protein and a further small molecule | |
US20210277107A1 (en) | Antibodies that bind cell surface grp78 and their use for detection of cancer | |
KR102638104B1 (en) | Bispecific HER2 and CD3 binding molecules | |
JP6385277B2 (en) | Anti-CEACAM1 recombinant antibody for cancer treatment | |
JP2023116746A (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
CN106211774B (en) | anti-CXCR 4 antibodies and antibody-drug conjugates | |
KR102159109B1 (en) | Anti il-36r antibodies | |
US9446124B2 (en) | Targeting of bone marrow neovasculature | |
JP2019506398A (en) | Epidermal growth factor receptor variant III and CD3 single and bispecific antibodies and their use | |
JP2024012382A (en) | Antibody specific to cd70, and use of the same | |
JP2005533493A (en) | Anti-IGF-I receptor antibody | |
JP2008520246A (en) | Antibody against vascular endothelial growth factor receptor-I | |
US20210324079A1 (en) | Bispecific her2 and cd3 binding molecules | |
JP2019535315A (en) | Immunoconjugates of IL2 and TNF mutants | |
JP2008500277A (en) | Anti-EpCAM immunoglobulin | |
US20200283518A1 (en) | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer | |
CA3051484A1 (en) | Bispecific her2 and cd3 binding molecules | |
JP2024504390A (en) | Anti-HER-2/TROP-2 constructs and uses thereof | |
CA3150987A1 (en) | Anti-ptcra antibody-drug conjugates and uses thereof | |
KR20060003860A (en) | Endothelial cell specific antibodies and uses thereof | |
JP2019516732A (en) | Anticancer combination treatment | |
WO2023148346A1 (en) | Combination therapy comprising anti-ccr9 antibody and vincristine for cancer | |
US20090110680A1 (en) | Combination of an anti ED-B fibronectin domain antibody and gemcitabine | |
WO2024023750A1 (en) | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor | |
KR20050021001A (en) | Anti-igf-i receptor antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081107 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20090119 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PHILOGEN S.P.A. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
DAX | Request for extension of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602007009373 Country of ref document: DE Date of ref document: 20101104 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Effective date: 20110204 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20100922 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101223 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110122 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110124 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20110623 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007009373 Country of ref document: DE Effective date: 20110623 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101222 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100922 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20160329 Year of fee payment: 10 Ref country code: AT Payment date: 20160324 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 481979 Country of ref document: AT Kind code of ref document: T Effective date: 20170405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170405 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20170430 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20180326 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170430 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20190501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190501 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20200327 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20200327 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20200507 Year of fee payment: 14 Ref country code: FR Payment date: 20200428 Year of fee payment: 14 Ref country code: DE Payment date: 20200429 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20200420 Year of fee payment: 14 Ref country code: IT Payment date: 20200325 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007009373 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210405 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211103 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210405 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210405 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210406 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200405 |